Verona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate Update
19 10월 2023 - 3:00PM
Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the
“Company”), a clinical-stage biopharmaceutical company focused on
respiratory diseases, announces that it will report its financial
results for the third quarter ended September 30, 2023 on Thursday,
November 2, 2023 and host an investment community conference call
at 9:00 a.m. EDT / 1:00 p.m. GMT to discuss these financial results
and provide a corporate update.
To participate, please dial one of the following
numbers and ask to join the Verona Pharma call:
- +1-833-816-1396 for callers in the
United States
- +1-412-317-0489
for international callers
A live webcast will be available on the Events
and Presentations link on the Investors page of the Company’s
website, www.veronapharma.com, and the audio replay will be
available for 90 days.
For further information please contact:
Verona Pharma plc |
US Tel: +1-833-417-0262UK Tel: +44 (0)203 283 4200 |
Victoria Stewart, Senior Director of Investor Relations and
Communications |
IR@veronapharma.com |
Argot PartnersUS Investor Enquiries |
Tel: +1-212-600-1902verona@argotpartners.com |
Ten Bridge CommunicationsInternational / US Media
Enquiries |
Tel:
+1-312-523-5016tbcverona@tenbridgecommunications.com |
Leslie Humbel |
|
About Verona Pharma
Verona Pharma is a clinical-stage
biopharmaceutical company focused on developing and commercializing
innovative therapies for the treatment of chronic respiratory
diseases with significant unmet medical needs. If successfully
developed and approved, Verona Pharma’s product candidate,
ensifentrine, has the potential to become the first non-steroidal
therapy for the treatment of respiratory diseases that combines
bronchodilator and anti-inflammatory activities in one molecule.
The Company has evaluated nebulized ensifentrine in its Phase 3
clinical program ENHANCE (“Ensifentrine as a Novel inHAled
Nebulized COPD thErapy”) for COPD maintenance treatment.
Ensifentrine met the primary endpoint in both ENHANCE-1 and
ENHANCE-2 trials demonstrating statistically significant and
clinically meaningful improvements in lung function. In addition,
ensifentrine substantially reduced the rate and risk of COPD
exacerbations in pooled analysis from ENHANCE-1 and ENHANCE-2. In
the third quarter of 2023, the US Food and Drug Administration
accepted for review the Company’s NDA for ensifentrine for the
maintenance treatment of patients with COPD and assigned a PDUFA
target action date of June 26, 2024. Two additional formulations of
ensifentrine have been evaluated in Phase 2 trials for the
treatment of COPD: dry powder inhaler (“DPI”) and pressurized
metered-dose inhaler (“pMDI”). Ensifentrine has potential
applications in cystic fibrosis, asthma and other respiratory
diseases. For more information, please
visit www.veronapharma.com.
Verona Pharma (NASDAQ:VRNA)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Verona Pharma (NASDAQ:VRNA)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024